Aspirin overcomes Navitoclax-resistance in hepatocellular carcinoma cells through suppression of Mcl-1

Biochemical and Biophysical Research Communications

Volumn 434, Issue 4, 2013, Pages 809-814

  Li, Gongquan ^a,b   Zhang, Shuijun ^a,b   Fang, Hongbo ^a,b   Yan, Bing ^a,b   Zhao, Yongfu ^a   Feng, Liushun ^a   Ma, Xiuxian ^a   Ye, Xuexiang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b Henan Key Laboratory of Digestive Organ Transplantation   (China)

Author keywords

Aspirin; Hepatocellular carcinoma; Mcl 1; Navitoclax (ABT 263)

Indexed keywords

ACETYLSALICYLIC ACID; CASPASE 3; CASPASE 9; CYTOCHROME C; NAVITOCLAX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN SECRETION; WESTERN BLOTTING;

ANILINE COMPOUNDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; ASPIRIN; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CELL SURVIVAL; CYSTEINE PROTEINASE INHIBITORS; CYTOCHROMES C; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; OLIGOPEPTIDES; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; SULFONAMIDES;

EID: 84878201766     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.04.018     Document Type: Article

References (33)

1. Burroughs A., Hochhauser D., Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol. 2004, 5:409-418.
2. Marrero J.A., Kudo M., Bronowicki J.-P. The challenge of prognosis and staging for hepatocellular carcinoma. Oncologist 2010, 15:23-33.
3. Elmore S. Apoptosis: a review of programmed cell death. Toxicol. Pathol. 2007, 35:495-516.
4. Schwartzman R.A., Cidlowski J.A. Apoptosis: the biochemistry and molecular biology of programmed cell death. Endocr. Rev. 1993, 14:133-151.
5. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
6. Jiang X., Wang X. Cytochromec-mediatedapoptosis. Annu. Rev. Biochem. 2004, 73:87-106.
7. Ren D., Tu H.C., Kim H., Wang G.X., Bean G.R., Takeuchi O., Jeffers J.R., Zambetti G.P., Hsieh J.J.D., Cheng E.H.Y. BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science 2010, 330:1390-1393.
8. Cory S., Huang D.C., Adams J.M. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003, 22:8590-8607.
9. Akgul C. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell. Mol. Life Sci. 2009, 66:1326-1336.
10. Kim R., Emi M., Tanabe K., Toge T. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy. Cancer 2004, 101:2491-2502.
11. Tse C., Shoemaker A.R., Adickes J., Anderson M.G., Chen J., Jin S., Johnson E.F., Marsh K.C., Mitten M.J., Nimmer P., Roberts L., Tahir S.K., Xiao Y., Yang X., Zhang H., Fesik S., Rosenberg S.H., Elmore S.W. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008, 68:3421-3428.
12. Cragg M.S., Harris C., Strasser A., Scott C.L. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat. Rev. Cancer 2009, 9:321-326.
13. Khaw S.L., Huang D.C., Roberts A.W. Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies. Pathol. J. RCPA 2011, 43:525-535.
14. Menzel T., Schauber J., Kreth F., Kudlich T., Melcher R., Gostner A., Scheppach W., Lührs H. Butyrate and aspirin in combination have an enhanced effect on apoptosis in human colorectal cancer cells. Eur. J. Cancer Prev. 2002, 11:271-281.
15. Shoemaker A.R., Mitten M.J., Adickes J., Ackler S., Refici M., Ferguson D., Oleksijew A., O'Connor J.M., Wang B., Frost D.J., Bauch J., Marsh K., Tahir S.K., Yang X., Tse C., Fesik S.W., Rosenberg S.H., Elmore S.W. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin. Cancer Res. 2008, 14:3268-3277.
16. Gandhi L., Camidge D.R., Ribeiro de Oliveira M., Bonomi P., Gandara D., Khaira D., Hann C.L., McKeegan E.M., Litvinovich E., Hemken P.M., Dive C., Enschede S.H., Nolan C., Chiu Y.L., Busman T., Xiong H., Krivoshik A.P., Humerickhouse R., Shapiro G.I., Rudin C.M. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J. Clin. Oncol. 2011, 29:909-916.
17. Hikita H., Takehara T., Shimizu S., Kodama T., Shigekawa M., Iwase K., Hayashi N. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hepatology 2010, 52:1310-1321.
18. Ackler S., Mitten M.J., Foster K., Oleksijew A., Refici M., Tahir S.K., Xiao Y., Tse C., Frost D.J., Fesik S.W. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother. Pharmacol. 2010, 66:869-880.
19. Wang G., Zhan Y., Wang H., Li W. ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein. Cancer Chemother. Pharmacol. 2012, 69:799-805.
20. Zhang S., Li G., Ma X., Wang Y., Liu G., Feng L., Zhao Y., Zhang G., Wu Y., Ye X., Qin B., Lu J. Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1. Cell. Signal. 2012, 24:1803-1809.
21. van Delft M.F., Wei A.H., Mason K.D., Vandenberg C.J., Chen L., Czabotar P.E., Willis S.N., Scott C.L., Day C.L., Cory S., Adams J.M., Roberts A.W., Huang D.C. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006, 10:389-399.
22. Park I.-S., Jo J.-R., Hong H., Nam K.-Y., Kim J.-B., Hwang S.-H., Choi M.-S., Ryu N.-H., Jang H.-J., Lee S.-H., Kim C.-S., Kwon T.-G., Park G.-Y., Park J.-W., Jang B.-C. Aspirin induces apoptosis in YD-8 human oral squamous carcinoma cells through activation of caspases, down-regulation of Mcl-1, and inactivation of ERK-1/2 and AKT. Toxicol. In Vitro 2010, 24:713-720.
23. Im S.-R., Jang Y.-J. Aspirin enhances TRAIL-induced apoptosis via regulation of ERK1/2 activation in human cervical cancer cells. Biochem. Biophys. Res. Commun. 2012, 424:65-70.
24. Iglesias-Serret D., Piqué M., Barragán M., Cosialls A.M., Santidrián A.F., González-Gironès D.M., Coll-Mulet L., Frias M., Pons G., Gil J. Aspirin induces apoptosis in human leukemia cells independently of NF-κB and MAPKs through alteration of the Mcl-1/Noxa balance. Apoptosis 2009, 15:219-229.
25. Song J.H., Kraft A.S. Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737. Cancer Res. 2011, 72:294-303.
26. Jacobs E.J., Thun M.J., Bain E.B., Rodriguez C., Henley S.J., Calle E.E. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. JNCI 2007, 99:608-615.
27. Harris R., Beebe-Donk J., Doss H. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol. Rep. 2005, 13:559.
28. Lu M., Strohecker A., Chen F., Kwan T., Bosman J., Jordan V.C., Cryns V.L. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels. Clin. Cancer Res. 2008, 14:3168-3176.
29. Yoo J., Lee Y. Aspirin enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. Mol. Pharmacol. 2007, 72:1586-1592.
30. Elwood P.C., Gallagher A.M., Duthie G.G., Mur L.A., Morgan G. Aspirin, salicylates, and cancer. Lancet (London, England) 2009, 373:1301-1309.
31. Yamaguchi R., Perkins G. Mcl-1 levels need not be lowered for cells to be sensitized for ABT-263/737-induced apoptosis. Cell Death Dis. 2011, 2:e227.
32. Keuling A., Parker A. RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway. PLoS ONE. 2009, 4:e6651.
33. Zhang C., Cai T.Y., Zhu H., Yang L.Q., Jiang H., Dong X.W., Hu Y.Z., Lin N.M., He Q.J., Yang B. Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1. Mol. Cancer Ther. 2011, 10:1264-1275.